Inve India ▾
TATARSONS

Tarsons Products Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 11 Aug 2026

Tarsons Products Limited reported a healthy Q1 FY27 with strong revenue growth across domestic and export markets. However, profitability was pressured by significant raw material price increases and higher costs from new facilities. The company is nearing completion of its large CAPEX program, with benefits expected to be more visible from FY28 as utilization ramps up and operating leverage improves.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

What they filed

Q1 FY27: revenue up 20.7%, net profit down 180.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue99 96 113 91 102 +3%108 +13%121 +7%110 +21%
EBITDA25 30 37 25 27 +8%32 +6%34 −7%26 +5%
Net profit10 5 10 2 3 −68%5 −4%4 −59%-1 −181%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.